Differential Proteomic and Genomic Comparison of Resistance Mechanism of Pseudomonas aeruginosa to Cefoperazone Sodium/Sulbactam Sodium

Cai, Shuangqi; Zhang, Ke-Xing; Wei, Fei; Yang, Lei; Song, Dezhi; Luo, Jin; Huang, Hong; Gao, Xingxin; DU, Gang; Kong, Jinliang; Chen, Yiqiang

doi:10.1590/0001-3765202220211160

Cited by 1 publication

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cai et al used protein and gene microarrays to compare wild‐type (WT) and drug‐resistant (DR) Pseudomonas aeruginosa. The results showed that there were 679 mutation sites in the DR Group, and the drug resistance rate of cefoperazone sodium/sulbactam sodium remained high from 2013 to 2015 23 …”

Section: Introductionmentioning

confidence: 99%

“…The results showed that there were 679 mutation sites in the DR Group, and the drug resistance rate of cefoperazone sodium/sulbactam sodium remained high from 2013 to 2015. 23 …”

Section: Introductionmentioning

confidence: 99%

“…The results showed that there were 679 mutation sites in the DR Group, and the drug resistance rate of cefoperazone sodium/sulbactam sodium remained high from 2013 to 2015. 23 We screened differentially expressed lncRNAs and mRNAs, predicting the associated pathways using gene microarray technology in LUAD-derived MPE. The lncRNA ZBED5-AS1 is located on chromosome 11p15.4, with a length of 1113 bp, and only one bioinformatic study has shown that it was associated with the development of ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Construction and analysis of expression profile of exosomal lncRNAs in pleural effusion in lung adenocarcinoma

Huang

Zhou

Yang

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Lung adenocarcinoma (LUAD) is a highly malignant tumor with a very low five‐year survival rate. In this study, we aimed to identify differentially expressed long‐chain non‐coding RNA (lncRNAs) and mRNAs from benign and malignant pleural effusion exosomes. Methods We used gene microassay and quantitative real‐time reverse transcription polymerase chain reaction (RT‐qPCR) to detect and verify differentially expressed mRNAs and lncRNAs in benign and malignant pleural effusion exosomes. Gene Ontology (GO) functional significance and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway significance enrichment analyses were performed to identify the difference in biological processes and functions between different mRNAs. We selected the lncRNA ZBED5‐AS1 with an upregulated differential fold of 3.003 and conducted a preliminary study on its cellular function. Results Gene microassay results revealed that 177 differentially expressed lncRNAs were upregulated, and 215 were downregulated. The top 10 upregulated were FMN1, AL118505.1, LINC00452, AL109811.2, CATG00000040683.1, AC137932.1, AC008619.1, AL450344.1, AC092718.6, and ZBED5‐AS1. The top 10 downregulated were TEX41, G067726, JAZF1‐AS1, AC027328.1, AL445645.1, AL022345.4, AC008572.1, AC123777.1, AC093714.1, and PHKG1. For the mRNAs, 79 were upregulated, and 123 were notably downregulated. GO analysis revealed that the upregulated differential mRNAs were mainly involved in “cellular response to acidic pH” (biological processes), “endoplasmic reticulum part” (cellular components), and “at DNA binding, cyclase activity” (molecular functions). KEGG pathways were found to be related to V. cholerae infection, Parkinson's disease, and cell adhesion molecules. RT‐qPCR showed that ZBED5‐AS1 was highly expressed in LUAD tissues, cells, and benign and malignant pleural fluid exosomes. Overexpression of ZBED5‐AS1 could significantly promote the proliferation, migration, invasion, and colony formation of LUAD cells, and knockdown had the opposite consequence. Conclusion The pleural effusion exosomes from patients with LUAD include several improperly expressed genes, and lncRNA‐ZBED5‐AS1 is a new biomarker that aids in our understanding of the occurrence and progression of LUAD.

show abstract

Section: Introductionmentioning

confidence: 99%

“…The results showed that there were 679 mutation sites in the DR Group, and the drug resistance rate of cefoperazone sodium/sulbactam sodium remained high from 2013 to 2015. 23 …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation